Cellectar Biosciences, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Cellectar Biosciences, Inc. (CLRB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $125.25 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-03-04
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $48.57.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2016-03-31 was $134.92.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $125.25, a 79.13% decline from fiscal 2024.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $600.00, a 92.79% decline from fiscal 2023.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $8325.00.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2016 was $156.53, a 35.26% decline from fiscal 2015.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $125.25 10-K · filed 2026-03-04 | ||||
| 2024-12-31 | $600.00 10-K · filed 2026-03-04 | $20.00 10-K · filed 2025-03-13 | |||
| 2023-12-31 | $8325.00 10-K · filed 2025-03-13 | ||||
| 2018-06-30 | $349.20 10-Q · filed 2018-08-10 | ||||
| 2018-03-31 | $48.57 10-Q · filed 2018-05-11 | ||||
| 2017-09-30 | $21420.00 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $0.00 10-Q · filed 2017-08-14 | ||||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-11 | ||||
| 2016-12-31 | $156.53 10-K · filed 2017-03-15 | ||||
| 2016-09-30 | $143.75 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $145.19 10-Q · filed 2016-08-11 | ||||
| 2016-03-31 | $134.92 10-Q · filed 2016-05-12 | ||||
| 2015-12-31 | $241.80 10-K · filed 2017-03-15 | ||||
| 2014-12-31 | $241.90 10-K/A · filed 2016-10-20 | ||||
| 2013-09-30 | $2.47 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |